Immunomodulators: interleukins, interferons, and the OKT3 monoclonal antibody

  • Daniel Abramowicz
  • Mary Meyer
  • Sandrine Florquin
  • Michel Goldman


Acute Renal Failure Acute Tubular Necrosis Delay Graft Function Nephrol Dial Transplant Procoagulant Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Luster MI, Simeonova PP, Gallucci R, Matheson J. Tumor necrosis factor a and toxicology. Crit Rev Toxicol 1999; 29(5): 491–511.CrossRefPubMedGoogle Scholar
  2. 2.
    Vassalli P. The pathophysiology of tumor necrosis factor. Annu Rev Immunol 1992; 10:411–452.CrossRefPubMedGoogle Scholar
  3. 3.
    Meldrum DR, Donnahoo KK. Role of TNF in mediating renal insufficiency following cardiac surgery: evidence of a post bypass cardiorenal syndrome. J Surg Res 1999; 85(2):185–199.CrossRefPubMedGoogle Scholar
  4. 4.
    Deasley D, Dinarello CA, Cannon JG. Interleukin-1 induces natriuresis in conscious rats: Role of renal prostaglandins. Kidney Int 1987; 33:1059–1065.Google Scholar
  5. 5.
    Bertani T, Abbate M, Zoja C, Corna D, Perico N, Ghezzi P, Remuzzi G. Tumor necrosis factor induces glomerular damage in the rabbit. Am J Pathol 1989; 134:419–430.PubMedGoogle Scholar
  6. 6.
    Giroir BP, Johnson JH, Allen GL, Beutler B. The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. J Clin Invest 1992; 90:693–698.PubMedGoogle Scholar
  7. 7.
    Dohan DE. Role of endothelin and tumor necrosis factor in the renal response to sepsis. Nephrol Dial Transplant 1994; 9:7377.Google Scholar
  8. 8.
    Wang J, Dunn MJ. Platelet-activating factor mediates endotoxin-induced acute renal insufficiency in rats. Am J Physiol 1987; 253:F1283–F1289.PubMedGoogle Scholar
  9. 9.
    Sedor JR. Interleukin-1: a master cytokine in the renal response to injury. In: Molecular Nephrology: Kidney Function in Health and Disease. Marcel Dekker, New York 1995; p. 631–652.Google Scholar
  10. 10.
    Tesch GH, Lan HY, Atkins RC, Nikolic-Paterson DJ. Role of interleukin-1 mesangial cell proliferation and matrix deposition in experimental mesangioproliferative nephritis. Am J Pathol 1997; 151(1):141–150.PubMedGoogle Scholar
  11. 11.
    Tesch GH, Yang N, Yu H, Lan HY, Foti R, Chadban SJ, Atkins RC, Nikolic-Paterson DJ. Intrinsic renal cells are the major source of interleukin-1 β synthesis in normal and disease. Nephrol Dial Transplant 1997; 12(6):1109–1115.PubMedGoogle Scholar
  12. 12.
    Ostendorf T, Burg M, Floege J. Cytokines and glomerular injury. Kidney Blood Press Res 1996; 19:281–289.PubMedGoogle Scholar
  13. 13.
    Al-Wakeel J, Mitwalli A, Tarif N, Al-Mohaya S, Malik G, Khalil M. Role of interferon-a in the treatment of primary glomerulonephritis. Am J Kidney Dis 1999; 33(6):1142–1146.PubMedGoogle Scholar
  14. 14.
    Maestroni GJ. The photoperiod transducer melatonin and the immune-hematopoietic system. J Photoch Photobiol 1998; 43A(3):186–192.Google Scholar
  15. 15.
    Stein GM, Berg PA. Mistletoe extract-induced effects on immunocompetent cells: in vitro studies. Anticancer Drugs 1997; 8(Suppl 1):S39–S42.PubMedGoogle Scholar
  16. 16.
    Stein GM, Berg PA. Modulation of cellular and humoral immune responses during exposure of healthy individuals to an aqueous mistletoe extract. Eur J Med Research 1998; 3(6):307–314.Google Scholar
  17. 17.
    Stein GM, Berg PA. Characterization of immunological reactivity of patients with adverse effects during therapy with an aqueous mistletoe extract. Eur J Med Research 1999; 4(5):169–177.Google Scholar
  18. 18.
    van Welly M, Stoss M, Gorter RW. Toxicity of a standardized mistletoe extract in immunocompromised and healthy individuals. Am J Therap 1999; 6(1):37–43.Google Scholar
  19. 19.
    Kunze E, Schulz H, Gabius HJ. Inability of galactoside-specific mistletoe lectin to inhibit N-methyl-N-nitrosurea-induced tumor development in the urinary bladder of rats and to mediate a local cellular immune response after long-term administration. J Cancer Res Clin Oncol 1998; 124(2):73–87.CrossRefPubMedGoogle Scholar
  20. 20.
    Davis ID. An overview of cancer immunotherapy. Immunol Cell Biol 2000; 78(3):179–195.CrossRefPubMedGoogle Scholar
  21. 21.
    Pinilla-Ibarz, J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, Lai L, Jimenez J, Kolitz J, Scheinberg DA. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 2000; 95(5):1781–1787.PubMedGoogle Scholar
  22. 22.
    Jayne DR, Chapel H, Adu D, Misbah S, O’Donoghue D, Scott D, Lockwood CM. Intravenous immunoglobin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000; 93(7):433–439.CrossRefPubMedGoogle Scholar
  23. 23.
    Tan E, Hajinazarian M, Bay W, Neff J, Mendell, JR. Acute renal failure resulting from intravenous immunoglobin therapy. Arch Neurol 1993; 50:137–139.PubMedGoogle Scholar
  24. 24.
    Kobosko J, Nicol P. Renal toxicity of intravenous immunoglobin. Clin Nephrol 1992; 37:216–217.PubMedGoogle Scholar
  25. 25.
    Barton JC, Herrera GA, Galla JH, Bertoli LF, Work J, Koopman WJ. Acute cryoglobulinemic renal failure after intravenous infusion of γ globulin. Am J Med 1987; 82:624–629.PubMedGoogle Scholar
  26. 26.
    Diluydy MS, Delclaux C, Deprecigout V, Haramburu F, Roger I, Deminiere C, Mercie P, Pellegrin JL, Aparicio M. Acute renal failure after polyvalent immunoglobulin therapy. Presse Medicale 2000; 29(17):942–943.Google Scholar
  27. 27.
    Green MC, Murray JL, Hortobagy GN. Monoclonal antibody therapy for solid tumors. Cancer Treat Rev 2000; 26(4):269–28.CrossRefPubMedGoogle Scholar
  28. 28.
    Stebbing J, Copson E, O’Reilly S. Herceptin in advanced breast cancer. Cancer Treat Rev 2000; 26:287–290.CrossRefPubMedGoogle Scholar
  29. 29.
    Gopal AK, Press OW. Clinical applications of anti-CD-20 antibodies. J Lab Clin Med 1999; 134(5):445–450.CrossRefPubMedGoogle Scholar
  30. 30.
    Nguyen DT, Amess JA, Doughty H, Hendry L, Diamond LW. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin’s lymphoma and lymphoproliferative disorders: evaluation of response in 48 patients. Eur J Haematol 1999; 62(2):76–82.PubMedGoogle Scholar
  31. 31.
    Van Deventer SJ. Immunotherapy of Crohn’s disease. Scand J Immunol 2000; 51(1):18–22.PubMedGoogle Scholar
  32. 32.
    Issacs JD, Burrows N, Wing M, Keogan MT, Rebello PR, Watts RA, Pye RJ, Norris P, Hazelman BL, Hale G, Waldmann H. Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease. Clin Exp Immunol 1997; 110(2):158–66.Google Scholar
  33. 33.
    Berard JL, Velez RL, Freeman RB, Tsunoda SM. A review of interleukin-2 receptor antagonists in solid organ transplantation. Pharmacotherapy 1999; 19(10):1127–1137.PubMedGoogle Scholar
  34. 34.
    Belldegrun A, Webb D, Austin H, Steinberg S, White D, Lineham W, Rosenberg S. Effects of Interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. Ann Intern Med 1987; 106:817–822.PubMedGoogle Scholar
  35. 35.
    Rosenberg S, Lotze M, Muul L, Chang A, Avis F, Leitman S, Linehan W, Robertson C, Lee R, Rubin J, Seipp C, Simpson C, White D. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukins-2 or high dose interleukins-2 alone. N Engl J Med 1987; 316:888–897.Google Scholar
  36. 36.
    Lotze M, Matory Y, Rayner A, Ettinghausen S, Vetto J, Seipp C, Rosenberg S. Clinical Effects and toxicity of interleukin-2 in patients with cancer. Cancer 1986; 58:2764–2772.PubMedGoogle Scholar
  37. 37.
    Margolin K, Rayner A, Hawkins M, Atkins M, Dutcher J, Fisher R, Weiss G, Doroshow J, Jaffe H, Roper M, Parkinson D, Wiernik P, Creekmore S, Boldt D. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 1989; 7:486–498.PubMedGoogle Scholar
  38. 38.
    Rosenstein M, Ettinghausen S, Rosenberg S. Extravasation of intravascular fluid mediated by the stemic administration of recombinant interleukins 2. J Immunol 1986; 137:1735–1742.PubMedGoogle Scholar
  39. 39.
    Schomburg A, Kirchner H, Atzpodien J. Renal, metabolic, and hemodynamic side-effects of itnerleukin-2 and/or interferon a: evidence of a risk/benefit advantage of subcutaneous therapy. J Cancer Res Clin Oncol 1993; 199(12):745–755.Google Scholar
  40. 40.
    Ponce P, Cruz J, Travassos J, Moreira P, Oliveira J, Melo-Gomes E, Gouveia J. Renal toxicity mediated by continuous infusion of recombinant interleukin-2. Nephron 1993; 64(1):114–118.PubMedGoogle Scholar
  41. 41.
    Memoli B, De Nicola L, Libetta C, Scialo A, Pacchiano G, Romano P, Palmieri G, Morabito A, Lauria R, Conte G et al. Interleukin-2 induced renal dysfunction in cancer patients is reversed by low-dose dopamine infusion. Am J Kidney Dis 1995; 26(1):27–33.PubMedGoogle Scholar
  42. 42.
    Palmieri G, Morabito A, Lauria R, Montesarchio V, Matano E, Memoli B, Libetta C, Rea A, Merola C, Correale P. Low-dose dopamine induces early recovery of recombinant interleukin-2 impaired renal function. Eur J Cancer 1993; 29A(8):1119–1122.PubMedGoogle Scholar
  43. 43.
    Rafi-lanajreh AQ, Chen D, Schmits R, Mak TW, Grayson RL, Sponeberg DP, Nagarkatti M, Nagarkatti PS. Evidence for the involvement of CD44 in endothelial cell injury and induction of vascular leak syndrome by IL-2. J Immunol 1999; 163(3):1619–1627.Google Scholar
  44. 44.
    Marroquin DE, White DE, Steinberg SM, Rosenberg SA, Schwartzentruber DJ. Decreased tolerance to interleukin-2 with repeated courses of therapy in patients with metastatic melanoma or renal cell cancer. J Immunother 2000; 23(3):387–392.PubMedGoogle Scholar
  45. 45.
    Textor S, Margolin K, Blayney D, Carlson J, Doroshow J. Renal, volume, and hormonal changes during therapeutic administration of recombinant interleukins-2 in man. Am J Med 1987; 83:1055–1061.CrossRefPubMedGoogle Scholar
  46. 46.
    Christiansen J, Skubitz K, Nath K, Ochoa A, Kennedy B. Nephrotoxicity of continuous intravenous infusion of recombinant interluekin-2. Am J Med 1988; 84; 1072–1075.CrossRefPubMedGoogle Scholar
  47. 47.
    Kozeny G, Nicholas J, Creekmore S, Sticklin L, Hano J, Risher R. Effects of interleukins-2 immunotherapy on renal function. J Clin Onc 1988; 6(7): 1770–1776.Google Scholar
  48. 48.
    Shalmi C, Dutcher J, Feinfeld D, Chun K, Saleemi K, Freeman L, Lynn R, Wiernik P. Acute renal dysfunction during interleukin-2 treatment: suggestion of an intrinsic renal lesion. J Clin Onc 1990; 8(11):1839–1846.Google Scholar
  49. 49.
    Hall T, James P, Cambridge G. Interleukin-2 nephrotoxicity assessed in vitro. Res Comm Chem Path Pharm 1991; 73(3): 375–378.Google Scholar
  50. 50.
    Vlasveld LT, van de Wiel-van Kemenade E, de Boer AJ, Sein JJ, Gallee MP, Krediet RT, Mellief CJ, Rankin EM, Hekman A, Figdor CG. Possible role for cytotoxic lymphocytes in the pathogenesis of acute interstitial nephritis after recombinant interleukin-2 treatment for renal cell cancer. Cancer Immunol Immunother 1993; 36(3): 210–213.CrossRefPubMedGoogle Scholar
  51. 51.
    Dutcher JP, Fisher RI, Weiss G, Aronson F, Margolin K, Louie A, Mier J, Caliendo G, Sosman JA, Eckardt JR, Ernest ML, Doroshow J, Atkins M. Outpatient subcutaneous interleukin-2 and interferon-a for metastatic renal cell cancer: five year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 1997; 3(3): 157–162.PubMedGoogle Scholar
  52. 52.
    Carson WE, Yu H, Dierksheide J, Pfeffer K, Bouchard P, Clark R, Durbin J, Baldwin AS, Peschon J, Johnson PR, Ku G, Baumann H, Caligiuri MA. A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells. J Immunol 1999; 162(8):4943–4951.PubMedGoogle Scholar
  53. 53.
    Phillips TM. Interferon-a induces renal dysfunction and injury. Curr Opin Nephrol Hypertens 1996; 5(4): 380–383.PubMedGoogle Scholar
  54. 54.
    Gutterman J, Fine S, Quesada J, Horning S, Levine J, Alexanian R, Bernhardt L, Kramer M, Spiegel H, Colburn W, Trown P, Merigan T, Dziewanowski Z. Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med 1982; 96(5): 549–556.PubMedGoogle Scholar
  55. 55.
    Abdulhay G, DiSaia P, Blessing J, Creasman W. Human lymphoblastoid interferon in the treatment of advanced epithelial ovarian malignancies: a gynecologic oncology group study. Am J Obstet Gynecol 1985; 152: 418–423.PubMedGoogle Scholar
  56. 56.
    Sherwin S, Knost J, Fein S. A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. JAMA 1982; 248: 2461–2466.CrossRefPubMedGoogle Scholar
  57. 57.
    Quesada J, Hawkins M, Horning S, Alexanian R, Borden E, Merigan T, Adams F, Gutterman J. Collaborative Phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma, and multiple myeloma. Am J Med 1984; 77: 427–432.CrossRefPubMedGoogle Scholar
  58. 58.
    Quesada J, Talpaz M, Rios A, Kurzrock R, Gutterman J. Clinical toxicity of interferons in cancer patients: a review. J Clin Onc 1986; 4(2): 234–243.Google Scholar
  59. 59.
    Ferri C, Marzo E, Longombardo G, Lombardini F, La Civita L, Vanacore R, Liberati A, Gerli R, Greco F, Moretti A, Monti M, Gentilini P, Bombardieri S, Zignego A. Interferon-α in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood 1993; 81(5): 1132–1136.PubMedGoogle Scholar
  60. 60.
    Dhib M, Bakhache E, Postec E, Vanrenterghem B, LeRoy F, Azar R, Francois A, Boldron A, Amaria R, Ozenne G, Hermelin A. Nephrotic syndrome complicating treatment with interferon α (Original title: Syndrome nephrotique compliquant un traitment par interferon α). Press Medicale 1996; 25(23): 1066–1068.Google Scholar
  61. 61.
    Dimitrov Y, Heibel F, Marcellin L, Chantrel F, Moulin B, Hannedouche T. Acute renal failure and nephrotic syndrome with α interferon therapy. Nephrol Dial Transplant 1997; 12(1): 200–203.PubMedGoogle Scholar
  62. 62.
    Gresser I, Maury C, Tovey M. Progressive glomerulonephritis in mice treated with interferon preparations at birth. Nature 1976; 263: 420–422.CrossRefPubMedGoogle Scholar
  63. 63.
    Morel-Maroger L, Sloper J, Vinter J, Woodrow D, Gresser I. An ultrastructural study of the development of nephritis in mice treated with interferon in the neonatal period. Lab Invest 1978; 39: 513–522.PubMedGoogle Scholar
  64. 64.
    Lederer E, Truong L. Unusual glomerular lesion in a patient receiving long-term interferon α. Am J Kidney Dis 1992; 20(5): 516–518.PubMedGoogle Scholar
  65. 65.
    Parker MG, Atkins MB, Ucci AA, Levey AS. Rapidly progressive glomerulonephritis after immunotherapy for cancer. J Am Soc Nephrol 1995; 5(10):1740–1744.PubMedGoogle Scholar
  66. 66.
    Selby P, Kohn J, Raymond J, Judson I, McElwain T. Nephrotic syndrome during treatment with interferon. Brit Med J 1985; 290: 1180–1181.Google Scholar
  67. 67.
    Herrman J, Gabriel F. Membranoproliferative glomerulonephritis in a patient with hairy-cell leukemia treated with α-II interferon. N Engl J Med 1987; 316(2): 112–113.PubMedGoogle Scholar
  68. 68.
    Averbuch S, Austin H, Sherwin S, Antonovych T, Bunn P, Longo D. N Engl J Med 1984; 310(1): 32–35.PubMedGoogle Scholar
  69. 69.
    Traynor A, Kuzel T, Samuelson E, Kanwar Y. Minimal change glomerulopathy and glomerular visceral epithelial hyperplasia associated with α-interferon therapy for cutaneous T-cell lymphoma. Nephron 1994; 67(1): 94–100.PubMedGoogle Scholar
  70. 70.
    Rettmar K, Kienast J, van de Loo J. Minimal change glomerulonephritis with reversible proteinuria during interferon α 2a therapy for chronic myeloid leukemia. Am J Hematol 1995; 49(4): 355–356.PubMedGoogle Scholar
  71. 71.
    Shah M, Jenis EH, Mookerjee BK, Schriber JR, Baer MR, Herzig GP, Wetzler M. Interferon-α associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy. Cancer 1998; 83(9): 1938–1946.CrossRefPubMedGoogle Scholar
  72. 72.
    Ravandi-Kashani F, Cortes J, Talpaz M, Kantarjian HM. Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect ? Cancer 1999; 85(12): 2583–2588.CrossRefPubMedGoogle Scholar
  73. 73.
    Harvey M, Rosenfeld D, Davies D, Hall BM. Recombinant interferon a and hemolytic uremic syndrome: cause or coincidence [letter]. Am J Hematol 1994; 46(2): 152–153.PubMedGoogle Scholar
  74. 74.
    Coronoes E, Petrusevska G, Varghese F, Truong LD. Focal segmental glomerulosclerosis with acute renal failure associated with α-interferon therapy. Am J Kidney Dis 1996; 28(6): 888–892.Google Scholar
  75. 75.
    Bellaiche G, Guettier C, Duboust A, Ley G, Slama JL. Nephrotic syndrome with acute renal failure due to focal segmental glomerulosclerosis in a patient treated with α-interferon for chronic hepatitis C. Gastroenterol Clin Biol 2000; 24(4): 465.PubMedGoogle Scholar
  76. 76.
    Gordon AC, Edgar JD, Finch RG. Acute exacerbation of vasculitis during interferon-a therapy for hepatitis C-associated cryoglobinaemia. J Infect 1998; 36(2): 229–230.CrossRefPubMedGoogle Scholar
  77. 77.
    Ohta S, Yokoyama H, Wada T, Sakai N, Shimizu M, Kato T, Furuichi K, Segawa C, Hisada Y, Kobayashi K. Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy. Am J Kidney Dis 1999; 33(6): 1040–1048.PubMedGoogle Scholar
  78. 78.
    Yamabe H, Johnson RJ, Gretch DR, Osawa H, Inuma H, Sasaki T, Kaizuka M, Tamura N, Tsunoda S, Fujita Y et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon-α. Am J Kidney Dis 1995; 25(1): 67–69.PubMedGoogle Scholar
  79. 79.
    Sarac E, Bastacky S, Johnson JP. Response to high-dose interferon α after failure of standard therapy in MPGN associated with hepatitis C virus infection. Am J Kidney Dis 1997; 30(1): 113–115.PubMedGoogle Scholar
  80. 80.
    Johnson RJ, Gretch DR, Couser WG, Alpers CE, Wilson J, Chung M, Hart J, Willson R. Heptatitis C virus associated glomerulonephritis. Effect of a interferon therapy. Kidney Int 1994; 46(6): 1700–1704.PubMedGoogle Scholar
  81. 81.
    Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Tkaczuk J, Durand D, Suc JM. Acute renal insufficiency in renal transplants treated with interferon-α for chronic hepatitis C (Original title: Insuffisance renale aigue chez des transplantes renaus traits par interferon-α pour une hepatatite chronique C. Néphrologie 1996; 17(4): 247–254.PubMedGoogle Scholar
  82. 82.
    Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D, Suc JM. Preliminary results of treatment of chronic hepatitis C with recombinant interferon a in renal transplant patients. Nephrol Dial Transplant 1995; 10 (Suppl 6):93–96.PubMedGoogle Scholar
  83. 83.
    Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D. Acute renal failure in kidney transplant patients treated with interferon α 2b for chronic hepatitis C. Nephron 1996; 74(3): 512–516.PubMedGoogle Scholar
  84. 84.
    Schiller J, Storer B, Willson J, Borden E. Phase I trial of combinations of recombinant interferons β and γ in patients with advanced malignancy. Cancer Treat Rep 1987; 71(10): 945–952.PubMedGoogle Scholar
  85. 85.
    Schiller J, Storer B, Witt P, Nelson B, Brown R, Horisberger M, Grossberg S, Border E. Biological and clinical effects of the combination of β and γ interferons administered as a 5 day continuous infusion. Cancer Res 1990; 50: 4588–4594.PubMedGoogle Scholar
  86. 86.
    Takei Y, Sims TN, Urmson J, Halloran PF. Central role for interferon γ receptor in the regulation of renal MHC expression. J Am Soc Nephrol 2000; 11(2): 250–261.PubMedGoogle Scholar
  87. 87.
    Thompson JA, Cox WW, Lindgren CG, Collins C, Neras KA, Bonnem EM, Fefer A. Subcutaneous recombinant γ interferon in cancer patients: toxicity, pharmacokinetics, and immunomodulatory effects. Cancer Immunol Immunother 1987; 25: 47–53.CrossRefPubMedGoogle Scholar
  88. 88.
    Sridkandan K, Garner P, Watkinson K, Pettingale K, Brinkley D, Calman F, Tee D. A toxicity study of recombinant interferon-γ given by intravenous infusion to patients with advanced cancer. Cancer Chemother Pharmacol 1986; 18: 63–68.Google Scholar
  89. 89.
    Ault B, Stapleton F, Gaber L, Martin A, Roy S, Murphy S. Acute renal failure during therapy with recombinant human γ interferon. N Engl J Med 1988; 319(21): 1397–1400.PubMedGoogle Scholar
  90. 90.
    Acuto, O. and E.L. Reinherz. The human T-cell receptor. Structure and function. N Engl J Med 1985: 312(17): 1100–1111.PubMedGoogle Scholar
  91. 91.
    Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313(6): 337–342.Google Scholar
  92. 92.
    Abramowicz D, Wissing M, Broeders N. Induction with anti-CD3 monoclonal antibodies. Current Opin Organ Transplant 1999; 4: 312–317.Google Scholar
  93. 93.
    Goldstein G. Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation. Transplant Proc 1987: 19(2 Suppl 1): 1–6.PubMedGoogle Scholar
  94. 94.
    Van Wauwe J, De Mey J Goossens J. OKT3: a monoclonal antibody with potent mitogenic properties. J Immunol 1980; 124: 2708–2713.PubMedGoogle Scholar
  95. 95.
    Abramowicz, D., L. Schandene, M. Goldman, A. Crusiaux, P. Vereerstraeten, L. De Pauw, J. Wybran, P. Kinnaert, E. Dupont and C. Toussaint. Release of tumor necrosis factor, interleukin-2, and γ-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989: 47(4): 606–608.PubMedGoogle Scholar
  96. 96.
    Chatenoud L, Ferran C, Reuter A, Legendre C, Gevaert Y, Kreis H, Franchimont P, Bach JF. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-γ. N Engl J Med 1989: 320(21): 1420–1421.PubMedGoogle Scholar
  97. 97.
    Chatenoud L, Ferran C, Legendre C, Thouard I, Merite S, Reuter A, Gevaert Y, Kreis H, Franchimont P, Bach JF. In vivo cell activation following OKT3 administration. Transplantation 1990: 49(4): 697–702.PubMedGoogle Scholar
  98. 98.
    Bloemena E, ten Berge IJM, Surachno J, Wilmink JM. Kinetics of interleukin 6 during OKT3 treatment in renal allograft recipients. Transplantation 1990: 50(2): 330–331.PubMedGoogle Scholar
  99. 99.
    Gaston RS, Deierhoi MH, Patterson T, Prasthofer E, Julian BA, Barber WH, Laskow DA, Diethelm AG, Curtis JJ. OKT3 first-dose reaction: association with T cell subsets and cytokine release. Kidney Int 1991: 39: 141–148.PubMedGoogle Scholar
  100. 100.
    Goldman M, Gérard C, Abramowicz D, Schandené L, Durez P, De Pauw L, Kinnaert P, Vereerstraeten P, Velu T. Induction of interleukin-6 and interleukin-10 by the OKT3 monoclonal antibody: possible relevance to posttransplant lymphoproliferative disorders. Clin Transplant 1992: 6: 265–268.Google Scholar
  101. 101.
    Ferran, C., F. Dautry, S. Merite, K. Sheehan, R. Schreiber, G. Grau, J.F. Bach and L. Chatenoud. Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo. J Clin Invest 1994: 93(5): 2189–2196.PubMedGoogle Scholar
  102. 102.
    Alegre M, Vandenabeele P, Flamand V, Moser M, Leo O, Abramowicz D, Urbain J, Fiers W, Goldman M. Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: role of tumor necrosis factor. Eur J Immunol 1990; 20(3): 707–710.PubMedGoogle Scholar
  103. 103.
    Ferran C, Dy M, Sheehan K, Schreiber R, Grau G, Bluestone J, Bach JF, Chatenoud L. Cascade modulation by anti-tumor necrosis factor monoclonal antibody of interferon-γ, interleukin 3 and interleukin 6 release after triggering of the CD3/T cell receptor activation pathway. Eur J Immunol 1991 21(10): 2349–2353.PubMedGoogle Scholar
  104. 104.
    Matthys P, Dillen C, Proost P, Heremans H, Van DJ, Billiau A. Modification of the anti-CD3-induced cytokine release syndrome by anti-interferon-γ or anti-interleukin-6 antibody treatment: protective effects and biphasic changes in blood cytokine levels. Eur J Immunol 1993: 23(9): 2209–2216.PubMedGoogle Scholar
  105. 105.
    Raasveld MH, Bemelman FJ, Schellekens PT, van Diepen FN, van Dongen A, van Royen EA, Hack CE, ten Berge IJ. Complement activation during OKT3 treatment: a possible explanation for respiratory side effects. Kidney Int 1993; 43(5): 1140–1149.PubMedGoogle Scholar
  106. 106.
    Vallhonrat H, Williams WW, Cosimi AB, Tolkoff-Rubin N, Ginns LC, Wain JC, Preffer F, Olszak I, Wee S, Delmonico FL, Pascual M. In vivo generation of C4d, Bb, iC3b, and SC5b-9 after OKT3 administration in kidney and lung transplant recipients. Transplantation 1999; 67(2): 253–258.PubMedGoogle Scholar
  107. 107.
    BÛsing M, Mellert J, Greger B, Hopt U. Acute pulmonary insufficiency due to OKT3 therapy. Transplant Proc 1990: 22: 1779.PubMedGoogle Scholar
  108. 108.
    Mackie JD, Pankewycz OG, Bastos MG, Kelley VE, Strom TB. Dose-related mechanisms of immunosuppression mediated by murine anti-CD3 monoclonal antibody in pancreatic islet cell and delayed-type hypersensitivity. Transplantation 1990: 49(6): 1150–1154.PubMedGoogle Scholar
  109. 109.
    Waid TH, Lucas BA, Thompson JA, Brown SA, Munch L, Prebeck RJ, Jezek D. Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients. Transplantation 1992; 53(1): 80–86.PubMedGoogle Scholar
  110. 110.
    Thistlethwaite J, Stuart JK, Mayes JT, Gaber AO, Woodle S, Buckingham MR, Stuart FP. Complications and monitoring of OKT3 therapy. Am J Kidney Dis 1988; 11(2): 112–119.PubMedGoogle Scholar
  111. 111.
    Kreis H. Adverse events associated with OKT3 immunosuppression in the prevention or treatment of allograft rejection. Clin Transplantation 1993: 7: 431–446.Google Scholar
  112. 112.
    Simpson MA, Madras PN, Cornaby AJ, Etienne T, Dempsey RA, Clowes GH, Monaco AP. Sequential determinations of urinary cytology and plasma and urinary lymphokines in the management of renal allograft recipients. Transplantation 1989: 47(2): 218–223.PubMedGoogle Scholar
  113. 113.
    Goldman, M., J.L. Van Laethem, D. Abramowicz, L. De Pauw, P. Kinnaert and P. Vereerstraeten. Evolution of renal function during treatment of kidney graft rejection with OKT3 monoclonal antibody. Transplantation 1990: 50(1): 158–159.PubMedGoogle Scholar
  114. 114.
    Batiuk TD, Bennett WM, Norman DJ. Cytokine nephropathy during antilymphocyte therapy. Transplant Proc 1993; 25(2 Suppl 1): 27–30.PubMedGoogle Scholar
  115. 115.
    Waid TH, Lucas BA, Thompson JS, McKeown JW, Brown S, Kryscio R, Skeeters LJ. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial. Transplantation 1997; 64(2): 274–281.PubMedGoogle Scholar
  116. 116.
    Woodle ES, Xu D, Zivin RA, Auger J, Charette J, O’Laughlin R, Peace D, Jollife LK, Haverty T, Bluestone JA, Thistlethwaite JR Jr. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3γ1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 1999; 68(5): 608–616.PubMedGoogle Scholar
  117. 117.
    Norman DJ, Kahana L, Stuart FP Jr, Thistlethwaite JR Jr, Shield CF 3rd, Monaco A, Dehlinger J, Wu SC, Van Horn A, Haverty TP. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993; 55(1): 44–50.PubMedGoogle Scholar
  118. 118.
    Opelz, G for The Collaborative Transplant Study. Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Transplantation 1995; 60(11): 1220–1224.PubMedGoogle Scholar
  119. 119.
    Abramowicz D, Norman D, Vereerstraeten P, Goldman M, De Pauw L, Vanherweghem JL, Kinnaert P, Kahana L, Thistlethwaite JR, Shield CF, Monaco AP, Shu-Chen Wu, Haverty T. OKT3 prophylaxis in renal grafts with prolonged ischemia times: association with improvement in long-term survival. Kidney Int 1996 49: 768–772.PubMedGoogle Scholar
  120. 120.
    Szczech LA, Berlin JA, Feldman HI. The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group. Ann Intern Med 1998; 128(10): 817–826.PubMedGoogle Scholar
  121. 121.
    Abramowicz D, Goldman M, De Pauw L, Kinnaert P, Vanherweghem Jl, Vereerstraeten P. Long-term effects of prophylactic OKT3 in cadaveric renal transplantation: a single-center, prospective, randomized study. Transplantation 1992; 54: 433–437.PubMedGoogle Scholar
  122. 122.
    Toussaint C, De Pauw L, Vereerstraeten P, Kinnaert P, Abramowicz D, Goldman M. Possible nephrotoxicity of the prophylactic use of OKT3 monoclonal antibody after cadaveric renal transplantation. Transplantation 1989; 48(3): 524–526.PubMedGoogle Scholar
  123. 123.
    Abramowicz D, Pradier O, Marchant A, Florquin S, De Pauw L, Vereerstraeten P, Kinnaert P, Vanherweghem JL, Goldman M. Induction of thromboses within renal grafts by high-dose prophylactic OKT3. Lancet 1992; 339(8796): 777–778.CrossRefPubMedGoogle Scholar
  124. 124.
    Abramowicz D, Pradier O, De Pauw L, Kinnaert P, Mat O, Surquin S, Doutrelepont JM, Vanherweghem JL, Capel P, Vereerstraeten P, Goldman M. High-dose glucocorticosteroids increase the procoagulant effects of OKT3. Kidney Int 1994; 46: 1596–1602.PubMedGoogle Scholar
  125. 125.
    Gomez E, Aguado S, Gago E, Escalada P, Alvarez-Grande J. Main graft vessels thromboses due to conventional-dose OKT3 in renal transplantation. Lancet 1992; 339(8809): 1612–1613.CrossRefPubMedGoogle Scholar
  126. 126.
    Noel C, Hazzan M, Coppin MC, Pruvot FR, Bridoux F, Lelievre G. Renal transplant artery thrombosis following treatment of allograft rejection with monoclonal anti-CD3 antibodies (OKT3). Transplant Proc 1995; 27(4): 2438–2439.PubMedGoogle Scholar
  127. 127.
    Shankar R, Bastani B, Salinas-Madrigal L, Sudarshan B. Acute thrombosis of the renal transplant artery after a single dose of OKT3. Am J Nephrol 2001; 21(2): 141–144.CrossRefPubMedGoogle Scholar
  128. 128.
    Heptinstall RH. Pathology of the kidney (3rd ed.). Little, Brown and Co; Boston 1983.Google Scholar
  129. 129.
    Dussol B, Brunet P, Vacher-Coponat H, Saingra Y, Casanova P, Berland Y. Haemolytic uraemic syndrome in a renal transplant recipient during OKT3 therapy. Nephrol Dial Transplant 1994; 9(8): 1191–1193.PubMedGoogle Scholar
  130. 130.
    Morris-Stiff G, Evans M, Baboolal K, Balaji V, Moore R, Jurewicz A, Lord R. Haemolytic uraemic syndrome associated with OKT3. Transpl Int 1996; 9(5): 522–523.CrossRefPubMedGoogle Scholar
  131. 131.
    Palleschi J, Novick AC, Braun WE, Magnusson MO. Vascular complications of renal transplantation. Urology 1980: 16(1): 61–67.CrossRefPubMedGoogle Scholar
  132. 132.
    Groggel GC. Acute thrombosis of the renal transplant artery: a case report and review of the literature. Clin Nephrol 1991: 36(1): 42–45.PubMedGoogle Scholar
  133. 133.
    Abramowicz D, De Pauw L, Le Moine A, Sermon F, Surquin M, Doutrelepont JM, Ickx B, Depierreux M, Vanherweghem JL, Kinnaert P, Goldman M, Vereerstraeten P. Prevention of OKT3 nephrotoxicity after kidney transplantation. Kidney Int 1996; 49: S39–S43.Google Scholar
  134. 134.
    Belldegrun A, Webb DE, Austin HA 3rd, Steinberg SM, White DE, Linehan WM, Rosenberg SA. Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. Ann Intern Med 1987; 106(6): 817–822.PubMedGoogle Scholar
  135. 135.
    Shalmi CL, Dutcher JP, Feinfeld DA, Chun KJ, Saleemi KR, Freeman LM, Lynn RI, Wiernik PH. Acute renal dysfunction during interleukin-2 treatment: suggestion of an intrinsic renal lesion. J Clin Oncol 1990: 8(11): 1839–1846.PubMedGoogle Scholar
  136. 136.
    Gresser I, Maury C, Tovey M, Morel-Maroger L, Pontillon F. Progressive Glomerulonephritis in mice treated with interferon preparations at birth. Nature 1976; 263: 420–422.CrossRefPubMedGoogle Scholar
  137. 137.
    Ault BH, Stapleton FB, Gaber L, Martin A, Roy S 3rd, Murphy SB. Acute renal failure during therapy with recombinant human γ interferon. N Engl J Med 1988; 319(21): 1397–1400.PubMedGoogle Scholar
  138. 138.
    Spriggs DR, Sherman ML, Michie H, Arthur KA, Imamura K, Wilmore D, Frei E, Kufe DW. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 1988: 80(13): 1039–1044.PubMedGoogle Scholar
  139. 139.
    Breisblatt WM, Schulman DS, Stein K, Wolfe CJ, Whiteside T, Kormos R, Hardesty RL. Hemodynamic response to OKT3 in orthotopic heart transplant recipients: evidence for reversible myocardial dysfunction. J Heart Lung Transplant 1991; 10(3): 359–365.PubMedGoogle Scholar
  140. 140.
    Ognibene FP, Rosenberg SA, Lotze M, Skibber J, Parker MM, Shelhamer JH, Parrillo JE. Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest 1988; 94(4): 750–754.PubMedGoogle Scholar
  141. 141.
    Natanson C, Eichenholz PW, Danner RL, Eichacker PQ, Hoffman WD, Kuo GC, Banks SM, MacVittie TJ, Parrillo JE. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med 1989: 169(3): 823–832.CrossRefPubMedGoogle Scholar
  142. 142.
    Quezado ZM, Natanson C. Systemic hemodynamic abnormalities and vasopressor therapy in sepsis and septic shock. Am J Kidney Dis 1992; 20(3): 214–222.PubMedGoogle Scholar
  143. 143.
    Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report [see comments]. N Engl J Med 1988: 319(25): 1676–1680.PubMedGoogle Scholar
  144. 144.
    Rosenstein M, Ettinghausen SE, Rosenberg SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 1986; 137(5): 1735–1742.PubMedGoogle Scholar
  145. 145.
    Thervet E, Martinez F, Legendre C, Dechaux M, Kreis H. First dose OKT3-induced release of endothelin in renal transplant recipients [letter]. Nephrol Dial Transplant 1993; 8(3): 287.Google Scholar
  146. 146.
    Clozel M, Clozel JP. Effects of endothelin on regional blood flows in squirrel monkeys. J Pharmacol Exp Ther 1989; 250(3): 1125–1131.PubMedGoogle Scholar
  147. 147.
    Maessen JG, Buurman WA, Kootstra G. Direct cytotoxic effect of cytokines in kidney parenchyma: a possible mechanism of allograft destruction. Transplant Proc 1989; 21: 309–310.PubMedGoogle Scholar
  148. 148.
    Damle NK, Doyle LV, Bender JR, Bradley EC. Interleukin 2-activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis. J Immunol 1987; 138(6): 1779–1785.PubMedGoogle Scholar
  149. 149.
    Linas SL, Shanley PF, Whittenburg D, Berger E, Repine JE. Neutrophils accentuate ischemia-reperfusion injury in isolated perfused rat kidneys. Am J Physiol 1988; 255: F728–F735.PubMedGoogle Scholar
  150. 150.
    Varani J, Ginsburg I, Schuger L, Gibbs DF, Bromberg J, Johnson KJ, Ryan US, Ward PA. Endothelial cell killing by neutrophils. Synergistic interaction of oxygen products and proteases. Am J Pathol 1989; 135(3): 435–438.PubMedGoogle Scholar
  151. 151.
    Schmaldienst S, Bohmig G, Pohanka E, Kovarik J, Zlabinger GJ. Evidence for granulocyte activation by OKT3. Transplant Proc 1992; 24(6): 2600–2601.PubMedGoogle Scholar
  152. 152.
    Linas SL, Whittenburg D, Parsons PE, Repine JE. Mild renal ischemia activates primed neutrophils to cause acute renal failure. Kidney Int 1992; 42(3): 610–616.PubMedGoogle Scholar
  153. 153.
    Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci USA 1987; 84(5): 1374–1378.PubMedGoogle Scholar
  154. 154.
    Hirsch R, Eckhaus M, Auchincloss HJ, Sachs DH, Bluestone JA. Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses. J Immunol 1988; 140(11): 3766–3772.PubMedGoogle Scholar
  155. 155.
    Ferran C, Sheehan K, Dy M, Schreiber R, Merite S, Landais P, Noel LH, Grau G, Bluestone J, Bach JF et al. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur J Immunol 1990; 20(3): 509–515.PubMedGoogle Scholar
  156. 156.
    Alegre ML, Vandenabeele P, Depierreux M, Florquin S, Deschodt Lanckman M, Flamand V, Moser M, Leo O, Urbain J, Fiers W, Goldman M. Cytokine release syndrome induced by the 145-2C11 anti-CD3 monoclonal antibody in mice: prevention by high doses of methylprednisolone. J Immunol 1991; 146(4): 1184–1191.PubMedGoogle Scholar
  157. 157.
    Heemann UW, Tullius SG, Kupiec-Weglinski JW, Tilney NL. Early events in acute allograft rejection: leukocyte/endothelial cell interactions. Clin Transplantation 1993; 7: 82–89.Google Scholar
  158. 158.
    Buysmann S, van Diepen FN, Surachno S, Pals ST, ten Berge RJ. Increased dermal expression of ICAM-1 and VCAM-1 after administration of OKT3 in man. Clin Nephrol 1996; 46(2): 84–91.PubMedGoogle Scholar
  159. 159.
    Bergese SD, Pelletier RP, Ohye RG, Vallera DA, Orosz CG. Treatment of mice with anti-CD3 mAb induces endothelial vascular cell adhesion molecule-1 expression. Transplantation 1994; 57(5): 711–717.PubMedGoogle Scholar
  160. 160.
    Bemelman FJ, Buysmann S, Yong SL, van Diepen FN, Schellekens PT, ten Berge RJ. Biphasic granulocytopenia after administration of the first dose of OKT3. Lab Clin Med 1995; 126(6): 571–579.Google Scholar
  161. 161.
    Pradier O, Surquin M, Stordeur P, De Pauw L, Kinnaert P, Vereerstraeten P, Capel P, Goldman M, Abramowicz D. Monocyte procoagulant activity induced by in vivo administration of the OKT3 monoclonal antibody. Blood 1996; 87: 3768–3774PubMedGoogle Scholar
  162. 162.
    Mannucci PM, Giangrande PL. Detection of the prethrombotic state due to procoagulant imbalance. Eur J Haematol 1992; 48(2): 65–69.PubMedGoogle Scholar
  163. 163.
    Pradier O, Marchant A, Abramowicz D, De Pauw L, Vereerstraeten P, Kinnaert P, Vanherweghem JL, Capel P, Goldman M. Procoagulant effect of the OKT3 monoclonal antibody: involvement of tumor necrosis factor. Kidney Int 1992; 42(5): 1124–1129.PubMedGoogle Scholar
  164. 164.
    Raasveld MH, Hack CE, ten Berge I. Activation of coagulation and fibrinolysis following OKT3 administration to renal transplant recipients: association with distinct mediators. Thromb Haemost 1992; 68(3): 264–267.PubMedGoogle Scholar
  165. 165.
    Deira J, Alberca I, Lerma JL, Martin B, Tabernero JM. Changes in coagulation and fibrinolysis in the postoperative period immediately after kidney transplantation in patients receiving OKT3 or cyclosporine A as induction therapy. Am J Kidney Dis 1998; 32(4): 575–581.PubMedGoogle Scholar
  166. 166.
    Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163(3): 740–745.CrossRefPubMedGoogle Scholar
  167. 167.
    Wu KK. Endothelial cells in hemostasis, thrombosis, and inflammation. Hosp Pract Off Ed 1992; 27(4): 145–150.PubMedGoogle Scholar
  168. 168.
    Itaka M, Iwatani Y, Row VV, Volpe R. Induction of monocyte procoagulant activity with OKT3 antibody. J Immunol 1987; 139: 1617–1623.Google Scholar
  169. 169.
    Pradier O, Abramowicz D, Capel P, Goldman M. Procoagulant properties of OKT3 at the monocyte level: inhibition by pentoxifylline. Transplant Proc 1993; 25: 39–40.PubMedGoogle Scholar
  170. 170.
    Ryan J, Geczy CL. Characterization and purification of mouse macrophage procoagulant-inducing factor. J Immunol 1986; 137(9): 2864–2870.PubMedGoogle Scholar
  171. 171.
    Zuckerman SH, Suprenant YM. Induction of endothelial cell/macrophage procoagulant activity: synergistic stimulation by γ interferon and granulocyte-macrophage colony stimulating factor. Thromb Haemost 1989; 61(2): 178–182.PubMedGoogle Scholar
  172. 172.
    Carlsen E, Flatmark A, Prydz H. Cytokine-induced procoagulant activity in monocytes and endothelial cells. Further enhancement by cyclosporine. Transplantation 1988; 46(4): 575–580.PubMedGoogle Scholar
  173. 173.
    Fan ST, Edgington TS. Clonal analysis of mechanisms of murine T helper cell collaboration with effector cells of macrophage lineage. J Immunol 1988; 141(6): 1819–1827.PubMedGoogle Scholar
  174. 174.
    Pradier O, Surquin M, Stordeur P, De Pauw L, Kinnaert P, Vereerstraeten P, Capel P, Goldman M, Abramowicz D. Monocyte procoagulant activity induced by in vivo administration of the OKT3 monoclonal antibody. Blood 1996; 87: 3768–3774.PubMedGoogle Scholar
  175. 175.
    Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci USA 1986; 83(10): 3460–3464.PubMedGoogle Scholar
  176. 176.
    Cotran RS, Pober JS. Effects of cytokines on vascular endothelium: their role in vascular and immune injury. Kidney Int 1989; 35(4): 969–975.PubMedGoogle Scholar
  177. 177.
    Emeis JJ, Kooistra T. Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986; 163(5): 1260–1266.CrossRefPubMedGoogle Scholar
  178. 178.
    van der Poll T, Levi M, Buller HR, van Deventer SJ, de Boer JP, Hack CE, ten Cate JW. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 1991; 174(3): 729–732.PubMedGoogle Scholar
  179. 179.
    Zavoico GB, Ewenstein BM, Schafer AI, Pober JS. IL-1 and related cytokines enhance thrombin-stimulated PGI2 production in cultured endothelial cells without affecting thrombin-stimulated von Willebrand factor secretion or platelet-activating factor biosynthesis. J Immunol 1989; 142(11): 3993–3999.PubMedGoogle Scholar
  180. 180.
    Lamas S, Michel T, Brenner BM, Marsden PA. Nitric oxide synthesis in endothelial cells: evidence for a pathway inducible by TNF-α. Am J Physiol 1991; 261: 634–641.Google Scholar
  181. 181.
    Beasley D, Schwartz JH, Brenner BM. Interleukin 1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells. J Clin Invest 1991; 87(2): 602–608.PubMedGoogle Scholar
  182. 182.
    Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990; 323(1): 27–36.PubMedGoogle Scholar
  183. 183.
    Konkle BA, Schuster SJ, Kelly MD, Harjes K, Hassett DE, Bohrer M, Tavassoli M. Plasminogen activator inhibitor-1 messenger RNA expression is induced in rat hepatocytes in vivo by dexamethasone. Blood 1992: 79(10): 2636–2642.PubMedGoogle Scholar
  184. 184.
    Vassalli JD, Hamilton J, Reich E. Macrophage plasminogen activator: modulation of enzyme production by anti-inflammatory steroids, mitotic inhibitors, and cyclic nucleotides. Cell 1976; 8: 271–281.CrossRefPubMedGoogle Scholar
  185. 185.
    Blajchman MA, Senyi AF, Hirsh J, Surya Y, Buchanan M. Shortening of bleeding time in rabbits by hydrocortisone caused by inhibition of prostacyclin generation by the vessel wall. J Clin Invest 1979; 63: 1026–1035.PubMedGoogle Scholar
  186. 186.
    Lewis GD, Campbell WB, Johnson AR. Inhibition of prostaglandin synthesis by glucocorticoids in human endothelial cells. Endocrinology 1986; 119(1): 62–69.PubMedGoogle Scholar
  187. 187.
    Knowles RG, Salter M, Brooks SL, Moncada S. Anti-inflammatory glucocorticoids inhibit the induction by endotoxin of nitric oxide synthase in the lung, liver and aorta of the rat. Biochem Biophys Res Commun 1990; 172(3): 1042–1048.CrossRefPubMedGoogle Scholar
  188. 188.
    Geller, D.A., A.K. Nussler, S.M. Di, C.J. Lowenstein, R.A. Shapiro, S.C. Wang, R.L. Simmons and T.R. Billiar. Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes. Proc Natl Acad Sci USA 1993: 90(2): 522–6.PubMedGoogle Scholar
  189. 189.
    Shen SMC, Rapaport SI. Increased fibrinogen consumption following endotoxin injection in cortisone-treated rabbits. Proc Soc Exp Biol Med 1974; 145: 851–854.PubMedGoogle Scholar
  190. 190.
    Ueda Y, Ito S, Saito K, Lee KH, Niesen N, Brentjens JR, Gans R. Divergent effects of cortisone on monocyte procoagulant activity and tumor necrosis factor release in the generalized Schwartzman reaction (GSR) in rabbits. J Am Soc Nephrol 1992; 2: 620.Google Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • Daniel Abramowicz
    • 1
  • Mary Meyer
    • 2
  • Sandrine Florquin
    • 3
  • Michel Goldman
    • 1
  1. 1.Hôpital ErasmeBrusselsBelgium
  2. 2.Oregon Health Sciences UniversityPortlandUSA
  3. 3.Academic Medical CenterAmsterdamThe Netherlands

Personalised recommendations